top of page



Our company holds an exclusive license to a patent for a novel, brain penetrating single-chain antibody to three-repeat tau.  Preclinical studies have shown that this antibody successfully crosses the blood brain barrier, selectively targets and reduces abnormal levels of three-repeat tau and phosphorylated tau without significantly affecting total tau levels, co-localizes with three-repeat tau and targets three-repeat tau to the eadosomal compartment for lysosomal degradation, reduces loss of neuronal cells and astrogliosis, and ameliorates behavioral deficits in both a pre-pulse inhibition paradigm as well as an open field beam break model.

We are currently in the process of completing pharmacokinetic and preliminary toxicology studies to advance the development of the antibody towards the eventual goal of an IND application.

Embryonic Stem Cells
Current Projects: About Us
bottom of page